

Figure 7. Effect of poly(I:C) on fibronectin release and collagen I production and effects of neutralizing anti–TGF-β antibody on the poly(I:C)-augmented fibronectin release and collagen I production. Fibroblasts were treated with various concentrations of poly(I:C). Media and cells were harvested. (*A*) Fibronectin release was measured by ELISA. (*B*) Collagen I expression was assessed by immunoblotting. Relative intensity was calculated by dividing each collagen I band intensity by each appropriate β-actin band intensity. To investigate the effects of neutralizing anti–TGF-β antibody on the (*C*) poly(I:C)-augmented fibronectin release and (*D*) collagen I production, cells were treated with various concentrations of poly(I:C) in the presence of neutralizing anti–TGF-β antibody or control IgG. All values are mean ± SEM for four to eight separate experiments. **P* < 0.05, ***P* < 0.01 compared with the values of control; ++*P* < 0.01 compared with the values of control IgG-pretreated poly(I:C)-treated group.

body. The effects of poly(I:C) on the profibrotic responses were also observed in normal adult lung fibroblasts. These data suggest that the activation of TLR3 can induce the differentiation of lung fibroblasts to myofibroblasts and stimulate excessive production of ECM proteins via an NF-κB–TGF-β_1 dependent pathway.

The respiratory tract is commonly exposed to various kinds of viruses. dsRNA is produced by many viruses in the infected cells during the replication (1); therefore, the activation of TLR3 commonly occurs in the infected cells of the lung during viral infection. Some viral infection, especially RSV and rhinovirus infection in childhood, is reported to be involved in the development of asthma (23). This may suggest that the signaling of TLRs could contribute to the development of asthma. Many studies have also shown that exacerbation of asthma occurs during various kinds of virus infection (24–26), whereas the precise mechanisms of viral-induced exacerbation in asthma are still unclear. Recently, the role of TLRs on viral infection has been elucidated, including their signal transduction (2, 3). Several recent papers focused on the role of TLRs, especially TLR3 in the pathogenesis of the disease exacerbation. In an *in vitro* study, activation of TLR3 by poly(I:C) enhanced the production of eosinophilic chemokines, including eotaxin and RANTES, in a variety of cells (8–10). In an asthmatic model, a previous report showed that treatment with poly(I:C) enhanced antigen sensitization, increased inflammatory cell infiltration in the airways, and enhanced methacholine airway hyperresponsiveness (11). These results suggest that dsRNA could play a key role in the development and exacerbation of asthma.

Airway remodeling is commonly observed in the airways of patients with asthma, and severe remodeling is thought to be a major cause of the irreversible airflow limitation in patients with refractory asthma (15, 27). Although various kinds of cells

TABLE 1. EFFECTS OF POLY(I:C) ON α-SMA EXPRESSION, TGF-β_1 AND FIBRONECTIN RELEASE, AND COLLAGEN I EXPRESSION IN NORMAL ADULT LUNG FIBROBLASTS

Poly(I:C) (μg/ml)	0	0.01	0.1	1	10
α-SMA expression (fold increase)	1.00 (0)	1.31 (0.23)	1.97 (0.39)	2.25 (0.17)	3.56* (0.62)
Total TGF-β_1 (pg/culture)	136 (8.6)	249 (67)	349 (120)	471 (110)	549* (100)
Active TGF-β_1 (pg/culture)	27.6 (6.3)	54.1 (9.9)	113* (22)	164* (31)	195* (23)
Fibronectin (ng/ml)	678.3 (180)	2,080 (527)	3,113* (658)	4,924* (623)	6,242* (411)
Collagen I expression (fold increase)	1.00 (0)	1.34 (0.17)	2.51 (0.78)	2.40 (0.39)	3.39* (0.61)

Definition of abbreviations: α-SMA, α-smooth muscle actin; poly(I:C), polyinosine-polycytidylic acid; TGF = transforming growth factor.

All values are mean (SEM).

* *P* < 0.01 compared with the values of control.

including epithelial cells, endothelial cells, and fibroblasts are involved in the airway remodeling, myofibroblasts are the most important cells among the resident cells in the airways (28). Myofibroblasts can produce greater amounts of ECM protein, including collagen I, III, V, fibronectin, and tenascin than "undifferentiated" fibroblasts (28). The deposition of excessive ECM proteins in the lamina reticularis of the basement membrane causes subepithelial fibrosis in the airways of asthma and results in the irreversible airflow limitation in patients with refractory asthma (29). In fact, the differentiation of fibroblasts to myofibroblasts was observed in the airways of a murine asthmatic model (18, 30) and in patients with severe asthma (31, 32). Although viral infection has been reported to induce airway remodeling in a murine asthmatic model (13, 33), there is no report regarding the role of TLR3 in the pathogenesis of airway remodeling. This is the first study to clarify the direct effect of dsRNA on the differentiation of fibroblasts to myofibroblasts. Because viral infection activates TLRs, the direct effect of dsRNA on the differentiation of fibroblasts to myofibroblasts may contribute to the progress of airway remodeling.

TGF-β is a key mediator of airway remodeling (34, 35) and is excessively produced in the airways of patients with asthma (21, 36, 37). To explore the mechanisms by which poly(I:C) augments α-SMA expression in fibroblasts, we investigated the fibroblast-mediated TGF-β_1 release in the present study. Poly(I:C) augmented the release of TGF-β_1 and neutralizing anti–TGF-β antibody inhibited the poly(I:C)-augmented α-SMA expression, suggesting that poly(I:C) facilitates the differentiation to myofibroblasts through TGF-β_1 release in an autocrine manner. Our finding is compatible with a pervious study showing that treatment with poly(I:C) increased the release of TGF-β_1 in the airways in a murine asthmatic model (11).

The gene expression of TGF-β_1 is regulated by some transcriptional factors including NF-κB (38, 39) and AP-1 (39, 40) by a direct or indirect mechanism. Broide and coworkers reported that TGF-β_1 release was increased in ovalbumin-challenged wild-type mice, whereas the TGF-β_1 level was decreased in IκB kinase knockout mice (41). In addition, the degree of the airway remodeling in the knockout mice was ameliorated. These results suggest that NF-κB activation is related to the pathogenesis of airway remodeling through TGF-β_1 release. Furthermore, many reports showed that poly(I:C) augmented the DNA-binding activity of NF-κB in a variety of cells (42–44). Therefore, we investigated the translocation of NF-κB into the nucleus in HFL-1 cells and found that poly(I:C) augmented NF-κB translocation into the nucleus as observed in other types of cells (42–44). In the current study, NF-κB inhibitors inhibited the release of TGF-β_1 and neutralizing anti–TGF-β antibody diminished the poly(I:C)-augmented α-SMA expression, suggesting that activation of TLR3 modulates the differentiation to myofibroblasts through the NF-κB–TGF-β_1 dependent pathway.

In the current study, we have also shown that poly(I:C) promotes the translocation of IRF-3 into the nucleus as shown in other types of cells (43, 44). However, the signaling of IRF-3 is not related to TGF-β_1 release. To our knowledge, there is no report regarding the relationship between IRF-3 signaling and the profibrotic responses. Considering the result of NF-κB inhibitors, the NF-κB signaling appears to be important for the TLR3-mediated TGF-β_1 release rather than that of IRF-3.

Excessive deposition of ECM proteins crucially contributes to airway remodeling. It has been reported that myofibroblasts can produce greater amount of ECM proteins compared with "undifferentiated" fibroblasts (31). TGF-β_1 reportedly induces ECM protein synthesis during the development of subepithelial fibrosis (45). Because the role of TLR3 on ECM production by human lung fibroblasts has not been elucidated, we investigated the effect of poly(I:C) on the production of ECM proteins. The current study demonstrated that poly(I:C) augmented fibronectin and collagen I production by HFL-1 cells and adult fibroblasts. This poly(I:C)-augmented ECM production was almost completely inhibited by neutralizing anti–TGF-β antibody. Taken together, poly(I:C) could enhance ECM production by the release of TGF-β_1.

In conclusion, the current study showed that poly(I:C) can enhance NF-κB activation and TGF-β_1 release in human lung fibroblasts, and consequently the differentiation to myofibroblasts and excessive ECM production are induced. The NF-κB–TGF-β_1 pathway is thought to play a pivotal role in the poly(I:C)-mediated differentiation of fibroblasts to myofibroblasts. Our data propose a possible mechanism for viral infection-induced airway remodeling. The modulation of this pathway may have therapeutic potential for airway remodeling induced by viral infection.

Conflict of Interest Statement: None of the authors has a financial relationship with a commercial entity that has an interest in the subject of this manuscript.

Acknowledgments: The authors thank Mr. Brent Bell for reading this manuscript.

References

1. Yang YL, Reis LF, Pavlovic J, Aguzzi A, Schäfer R, Kumar A, Williams BR, Aguet M, Weissmann C. Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. *EMBO J* 1995;14:6095–6106.
2. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. *Cell* 2006;124:783–801.
3. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. *Cell* 1996;86:973–983.
4. Gern JE, Rosenthal LA, Sorkness RL, Lemanske RF Jr. Effects of viral respiratory infections on lung development and childhood asthma. *J Allergy Clin Immunol* 2005;115:668–674.
5. Schaller M, Hogaboam CM, Lukacs N, Kunkel SL. Respiratory viral infections drive chemokine expression and exacerbate the asthmatic response. *J Allergy Clin Immunol* 2006;118:295–302.
6. Kotaniemi-Syrjänen A, Vainionpää R, Reijonen TM, Waris M, Korhonen K, Korppi M. Rhinovirus-induced wheezing in infancy-the first sign of childhood asthma? *J Allergy Clin Immunol* 2003;111:66–71.
7. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. *BMJ* 1993;307:982–986.
8. Papadopoulos NG, Papi A, Meyer J, Stanciu LA, Salvi S, Holgate ST, Johnston SL. Rhinovirus infection up-regulates eotaxin and eotaxin-2 expression in bronchial epithelial cells. *Clin Exp Allergy* 2001;31:1060–1066.
9. Becker S, Reed W, Henderson FW, Noah TL. RSV infection of human airway epithelial cells causes production of the beta-chemokine RANTES. *Am J Physiol* 1997;272:L512–L520.
10. Niimi K, Asano K, Shiraishi Y, Nakajima T, Wakaki M, Kagyo J, Takihara T, Suzuki Y, Fukunaga K, Shiomi T, *et al.* TLR3-mediated synthesis and release of eotaxin-1/CCL11 from human bronchial smooth muscle cells stimulated with double-stranded RNA. *J Immunol* 2007;178:489–495.
11. Jeon SG, Oh SY, Park HK, Kim YS, Shim EJ, Lee HS, Oh MH, Bang B, Chun EY, Kim SH, *et al.* TH2 and TH1 lung inflammation induced by airway allergen sensitization with low and high doses of double-stranded RNA. *J Allergy Clin Immunol* 2007;120:803–812.
12. Psarras S, Volonaki E, Skevaki CL, Xatzipsalti M, Bossios A, Pratsinis H, Tsigkos S, Gourgiotis D, Constantopoulos AG, Papapetropoulos A, *et al.* Vascular endothelial growth factor-mediated induction of angiogenesis by human rhinoviruses. *J Allergy Clin Immunol* 2006;117:291–297.
13. Walter MJ, Morton JD, Kajiwara N, Agapov E, Holtzman MJ. Viral induction of a chronic asthma phenotype and genetic segregation from the acute response. *J Clin Invest* 2002;110:165–175.
14. Bossios A, Psarras S, Gourgiotis D, Skevaki CL, Constantopoulos AG, Saxoni-Papageorgiou P, Papadopoulos NG. Rhinovirus infection induces cytotoxicity and delays wound healing in bronchial epithelial cells. *Respir Res* 2005;6:114.

15. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. *Am J Respir Crit Care Med* 2000;162:2341–2351.
16. Plante S, Semlali A, Joubert P, Bissonnette E, Laviolette M, Hamid Q, Chakir J. Mast cells regulate procollagen I (alpha 1) production by bronchial fibroblasts derived from subjects with asthma through IL-4/IL-4 delta 2 ratio. *J Allergy Clin Immunol* 2006;117:1321–1327.
17. Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, Barnes N, Robinson D, Kay AB. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. *J Clin Invest* 2003;112:1029–1036.
18. Sugiura H, Liu X, Duan F, Kawasaki S, Togo S, Kamio K, Wang XQ, Mao L, Ahn Y, Ertl RF, *et al.* Cultured lung fibroblasts from ovalbumin-challenged "asthmatic" mice differ functionally from normal. *Am J Respir Cell Mol Biol* 2007;37:424–430.
19. Carroll NG, Perry S, Karkhanis A, Harji S, Butt J, James AL, Green FH. The airway longitudinal elastic fiber network and mucosal folding in patients with asthma. *Am J Respir Crit Care Med* 2000;161:244–248.
20. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. *N Engl J Med* 2000;342:1350–1358.
21. Minshall EM, Leung DY, Martin RJ, Song YL, Cameron L, Ernst P, Hamid Q. Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. *Am J Respir Cell Mol Biol* 1997; 17:326–333.
22. Sugiura H, Liu X, Kobayashi T, Togo S, Ertl RF, Kawasaki S, Kamio K, Wang XQ, Mao L, Shen L, *et al.* Reactive nitrogen species augment fibroblast-mediated collagen gel contraction, mediator production, and chemotaxis. *Am J Respir Cell Mol Biol* 2006;34:592–599.
23. Singh AM, Moore PE, Gern JE, Lemanske RF Jr, Hartert TV. Bronchiolitis to asthma: a review and call for studies of gene-virus interactions in asthma causation. *Am J Respir Crit Care Med* 2007; 175:108–119.
24. Bartlett NW, Walton RP, Edwards MR, Aniscenko J, Caramori G, Zhu J, Glanville N, Choy KJ, Jourdan P, Burnet J, *et al.* Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. *Nat Med* 2008;14:199–204.
25. Lemanske RF Jr, Busse WW. Asthma: factors underlying inception, exacerbation, and disease progression. *J Allergy Clin Immunol* 2006; 117:S456–S461.
26. Mallia P, Johnston SL. How viral infections cause exacerbation of airway diseases. *Chest* 2006;130:1203–1210.
27. Busse WW, Banks-Schlegel S, Wenzel SE. Pathophysiology of severe asthma. *J Allergy Clin Immunol* 2000;106:1033–1042.
28. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. *J Pathol* 2003;200:500–503.
29. Hocking DC. Fibronectin matrix deposition and cell contractility: implications for airway remodeling in asthma. *Chest* 2002;122:275S–278S.
30. Schmidt M, Sun G, Stacey MA, Mori L, Mattoli S. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. *J Immunol* 2003;171:380–389.
31. Brewster CE, Howarth PH, Djukanovic R, Wilson J, Holgate ST, Roche WR. Myofibroblasts and subepithelial fibrosis in bronchial asthma. *Am J Respir Cell Mol Biol* 1990;3:507–511.
32. Holtzman MJ, Morton JD, Shornick LP, Tyner JW, O'Sullivan MP, Antao A, Lo M, Castro M, Walter MJ. Immunity, inflammation, and remodeling in the airway epithelial barrier: epithelial-viral-allergic paradigm. *Physiol Rev* 2002;82:19–46.
33. Kenyon NJ, Ward RW, Last JA. Airway fibrosis in a mouse model of airway inflammation. *Toxicol Appl Pharmacol* 2003;186:90–100.
34. McMillan SJ, Xanthou G, Lloyd CM. Manipulation of allergen-induced airway remodeling by treatment with anti-TGF-beta antibody: effect on the Smad signaling pathway. *J Immunol* 2005;174:5774–5780.
35. Vignola AM, Chanez P, Chiappara G, Merendino A, Pace E, Rizzo A, la Rocca AM, Bellia V, Bonsignore G, Bousquet J. Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis. *Am J Respir Crit Care Med* 1997;156:591–599.
36. Cohn L, Elias JA, Chupp GL. Asthma: mechanisms of disease persistence and progression. *Annu Rev Immunol* 2004;22:789–815.
37. Lee KY, Ho SC, Lin HC, Lin SM, Liu CY, Huang CD, Wang CH, Chung KF, Kuo HP. Neutrophil-derived elastase induces TGF-beta1 secretion in human airway smooth muscle via NF-kappaB pathway. *Am J Respir Cell Mol Biol* 2006;35:407–414.
38. Lee KY, Ito K, Hayashi R, Jazrawi EP, Barnes PJ, Adcock IM. NF-kappaB and activator protein 1 response elements and the role of histone modifications in IL-1beta-induced TGF-beta1 gene transcription. *J Immunol* 2006;176:603–615.
39. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. *Nat Med* 2006;12:99–106.
40. Broide DH, Lawrence T, Doherty T, Cho JY, Miller M, McElwain K, McElwain S, Karin M. Allergen-induced peribronchial fibrosis and mucus production mediated by IkappaB kinase beta-dependent genes in airway epithelium. *Proc Natl Acad Sci USA* 2005;102:17723–17728.
41. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. *Nature* 2001;413:732–738.
42. Takeuchi O, Akira S. Recognition of viruses by innate immunity. *Immunol Rev* 2007;220:214–224.
43. Zhang SY, Jouanguy E, Sancho-Shimizu V, von Bernuth H, Yang K, Abel L, Picard C, Puel A, Casanova JL. Human Toll-like receptor-dependent induction of interferons in protective immunity to viruses. *Immunol Rev* 2007;220:225–236.
44. Makinde T, Murphy RF, Agrawal DK. The regulatory role of TGF-beta in airway remodeling in asthma. *Immunol Cell Biol* 2007;85:348–356.

Allergology International. 2009;58:307-313
DOI: 10.2332/allergolint.09-RAI-0106
REVIEW ARTICLE

Differences of Inflammatory Mechanisms in Asthma and COPD

Masakazu Ichinose[1]

ABSTRACT
Bronchial asthma and chronic obstructive pulmonary disease (COPD) are increasing common diseases. The major pathogenesis of both illnesses is chronic inflammation. However, the inflammatory pattern is distinct in each disease. In asthmatic airways, activated mast cells/eosinophils and T helper 2 lymphocytes (Th2) are predominant. In contrast, macrophages and neutrophils are important in COPD airways/lung. Although nitric oxide (NO) hyperproduction due to inducible NO synthase (iNOS) is observed in asthma and COPD, nitrotyrosine formation via the reaction between NO and O_2^- in addition to the myeloperoxidase-mediated pathway. These distinct inflammatory patterns in both diseases seem to cause pathological differences in asthma and COPD.

KEY WORDS
bronchomotor tone, inflammatory cells, nitric oxide, oxidative stress, tachykinins

INTRODUCTION

Both bronchial asthma and chronic obstructive pulmonary disease (COPD) are defined as inflammatory diseases in recent worldwide guidelines,[1,2] although the inflammatory process for each disease is different. In this review, I describe some differences in the inflammatory processes in each disease.

INFLAMMATORY CELL INFILTRATION

Bronchial asthma is characterized as chronic airway inflammation from the central to the peripheral airways involving various cell types such as activated mast cells/eosinophils and T helper 2 lymphocytes (Th2), which release mediators that contribute to asthma symptoms (Table 1).[1,3-10] Actually, many cytokines and growth factors such as IL-4, IL-5, and GM-CSF can be monitored with exhaled breath condensate (EBC) (Table 2).[11] Clinically, examination of the eosinophil infiltration into the airways (sputum) is useful for discriminating asthma from COPD.[12,13]

On the other hand, in COPD, the inflammatory cells that infiltrate into the airways/lung are different (Fig. 1).[13] Macrophages are increased in the lungs of patients with asthma and COPD, however, they are more increased in COPD than in asthma. These macrophages are derived from circulating monocytes, which migrate to the lungs in response to chemoattractants such as CC-chemokine ligand 2 (CCL2), also known as MCP1, acting on CCR2, and CXCL1 acting on CXCR2.[14]

Neutrophils are also increased in the sputum of patients with COPD and are correlated with the disease severity.[15]

However, during exacerbations in both diseases, inflammatory cell infiltration into the airways becomes less selective, that is, there is neutrophil infiltration in asthma and eosinophil accumulation in COPD, possibly due to virus-induced chemokine production via the epithelium.

MEDIATORS THAT ACT ON THE BRONCHOMOTOR TONE

In asthma, cysteinyl leukotrienes are potent bronchoconstrictors and proinflammatory mediators mainly derived from mast cells and eosinophils. They are the only mediator whose inhibition has been associated with an improvement in lung function and asthma symptoms.[1,16] Histamine and prostaglandins are also released from mainly mast cells and contribute to the bronchomotor tone in asthma.[1] Therefore, functional antagonists, such as β2-stimulants, cause more potent bronchodilation than anti-cholinergic agents in bronchial asthma.

[1]Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Correspondence: Masakazu Ichinose, Third Department of Internal Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-0012, Japan.
Email: masakazu@wakayama-med.ac.jp
Received 29 March 2009.
©2009 Japanese Society of Allergology

Table 1 Inflammatory cells in asthmatic airways

Mast cells: Activated mucosal mast cells release bronchoconstrictor mediators (histamine, cysteinyl leukotrienes, prostaglandin D2) (3). These cells are activated by allergens through high-affinity IgE receptors, as well as by osmotic stimuli (accounting for exercise-induced bronchoconstriction). Increased mast cell numbers in airway smooth muscle may be linked to airway hyperresponsiveness (4).

Eosinophils, present in increased numbers in the airways, release basic proteins that may damage airway epithelial cells. They may also have a role in the release of growth factors and airway remodeling (5).

T lymphocytes, present in increased numbers in the airways, release specific cytokines, including IL-4, IL-5, IL-9, and IL-13, that orchestrate eosinophilic inflammation and IgE production by B lymphocytes (6). An increase in Th2 cell activity may be due in part to a reduction in regulatory T cells that normally inhibit Th2 cells. There may also be an increase in invariant T cells, which release large amounts of T helper 1 (Th1) and Th2 cytokines (7).

Dendritic cells sample allergens from the airway surface and migrate to regional lymph nodes, where they interact with regulatory T cells and ultimately stimulate the production of Th2 cells from naïve T cells (8).

Macrophages are increased in the airways and may be activated by allergens through low-affinity IgE receptors to release inflammatory mediators and cytokines that amplify the inflammatory response (9).

Neutrophils are increased in the airways and sputum of patients with severe asthma and in smoking asthmatics, but the pathophysiological role of these cells is uncertain and their increase may even be due to glucocorticosteroid therapy (10).

Reproduced from reference 1.

Table 2 Relative cytokine levels to positive control in exhaled breath condensates (EBC) obtained from either healthy subjects (a) or asthmatic subjects (b)

Cytokine	Control subjects (%)[(a)]	Asthmatic subjects (%)[(b)]	Fold increase[(b/a)]	Cytokine	Control subjects (%)[(a)]	Asthmatic subjects (%)[(b)]	Fold increase[(b/a)]
IL-1α	4.0 ± 2.1	5.2 ± 1.3	1.30	IL-8	5.4 ± 2.1	8.3 ± 1.9*	1.52
IL-1β	4.6 ± 0.9	4.2 ± 2.0	0.92	Mig	4.2 ± 1.4	4.1 ± 1.5	0.97
IL-2	4.9 ± 1.7	4.1 ± 2.0	0.83	IP-10	8.4 ± 1.3	22.7 ± 6.4*	2.72
IL-3	5.7 ± 1.4	5.0 ± 2.0	0.88	I-309	3.5 ± 1.5	3.5 ± 2.2	1.00
IL-4	5.2 ± 1.7	8.2 ± 1.6*	1.56	MIP-1α	6.3 ± 1.3	9.2 ± 2.0*	1.47
IL-6	5.2 ± 1.2	4.7 ± 1.7	0.91	MIP-1β	6.5 ± 1.5	10.2 ± 3.7*	1.58
IL-6sR	5.1 ± 1.3	4.6 ± 1.8	0.91	MIP-1δ	3.7 ± 1.3	5.4 ± 2.9	1.45
IL-7	2.6 ± 0.8	3.2 ± 1.5	1.24	RANTES	6.2 ± 1.5	10.4 ± 2.5*	1.69
IL-10	5.4 ± 1.8	5.7 ± 1.6	1.04	MCP-1	6.5 ± 2.1	7.9 ± 2.2	1.20
IL-11	5.6 ± 1.8	5.2 ± 1.8	0.93	MCP-2	4.1 ± 1.7	4.3 ± 1.5	1.04
IL-12 p40	4.8 ± 1.4	4.2 ± 1.8	0.88	Eotaxin-1	4.6 ± 2.2	5.0 ± 2.3	1.09
IL-12 p70	2.8 ± 1.4	3.4 ± 2.1	1.24	Eotaxin-2	3.9 ± 1.7	4.3 ± 1.3	1.11
IL-13	4.0 ± 1.0	5.5 ± 2.3	1.37	G-CSF	3.6 ± 1.7	3.1 ± 1.5	0.88
IL-15	7.3 ± 2.8	7.4 ± 3.4	1.01	GM-CSF	3.8 ± 1.0	3.4 ± 1.6	0.92
IL-16	6.2 ± 1.8	6.5 ± 4.3	1.04	M-CSF	9.7 ± 3.4	9.4 ± 4.7	0.97
IL-17	8.6 ± 1.5	12.6 ± 4.1*	1.46	TGF-β	6.6 ± 1.2	11.6 ± 3.4*	1.69
TNF-α	7.0 ± 1.0	12.4 ± 3.8*	1.76	PDGF	6.8 ± 1.6	7.6 ± 1.8	1.12
TNF-β	27.7 ± 7.4	27.6 ± 8.3	1.00	TIMP-2	9.5 ± 2.9	9.0 ± 3.0	0.94
sTNF RI	4.8 ± 1.8	5.4 ± 1.4	1.13	ICAM-1	3.4 ± 0.8	3.4 ± 2.1	1.00
sTNF RII	5.1 ± 1.6	4.6 ± 1.5	0.90	IFN-γ	5.4 ± 2.2	5.5 ± 2.2	1.00

Abbreviations: Mig, monokine induced by IFN-g; IL-6sR, IL-6 soluble receptor; MCP, monocyte chemoattractant protein; G-CSF, granulocyte colony-stimulating factor; M-CSF, macrophage colony-stimulating factor; PDGF, platelet-derived growth factor; TIMP-2, tissue inhibitor of metalloprotease 2; sTNF-R, soluble TNF receptor; ICAM-1, intracellular adhesion molecule 1. *$P < .01$ compared with control subjects. Reproduced from reference 5.



Fig. 1 Inflammatory cells involved in COPD. Inhaled cigarette smoke activates epithelial cells and macrophages to release several chemotactic factors that attract inflammatory cells to the lungs, such as CC-chemokine ligand 2 (CCL2), which acts on CC-chemokine receptor 2 (CCR2) to attract monocytes, CXC-chemokine ligand 1 (CXCL1) and CXCL8, which act on CCR2 to attract neutrophils and monocytes (which differentiate into macrophages in the lungs) and CXCL9, CXCL10 and CXCL11, which act on CXCR3 to attract T helper 1 (TH1) cells and type 1 cytotoxic T (TC1) cells. These inflammatory cells together with macrophages and epithelial cells release proteases, such as matrix metalloproteinase 9 (MMP9), which cause elastin degradation and emphysema. Neutrophil elastase also causes mucus hypersecretion. Epithelial cells and macrophages also release transforming growth factor-β (TGFβ), which stimulates fibroblast proliferation, resulting in fibrosis in the small airways. Reproduced from reference 13.

In contrast, in COPD patients, such inflammatory mediators are not important for the bronchomotor tone. In COPD airways, anti-cholinergic agents shows more obvious bronchodilatory effects than β2-stimulants, indicating that vagal nerve-derived acetylcholine is the only bronchoconstrictive (reversible) mechanism in this disease.[17]

TACHYKININS

Because tachykinins, such as substance P (SP) and neurokinin A (NKA), are potent stimulants of submucosal glands and goblet cell secretion,[16] these peptides seem to be involved in the inflammatory process in asthma and COPD. Increased SP concentrations have been reported in the induced sputum of patients with asthma and COPD compared with healthy individuals (Fig. 2).[18] SP is metabolized by neutral endpeptidase (NEP),[19] which exists in the respiratory epithelium. In asthmatic airways, epithelium shedding caused by eosinophil-derived major basic protein (MBP)[20,21] leads to dysfunction of the NEP, which may enhance the tachykinins' function. Actually, there was a significant relation between the eosinophil count and SP concentration in the induced sputum from patients with asthma but not in that from COPD subjects.[18] These data suggest that SP



Fig. 2 Left panel: Substance P (SP) concentration in hypertonic saline-induced sputum. Bars indicate mean values. Right panel: Relation between SP concentration and FEV_1/FVC. r is correlation coefficient; the line and p value correspond to the fitted regression equation. Reproduced from reference 18 with modification.

hypo-degradation due to epithelial loss may be the cause of the elevated SP levels in asthmatic airways. Tachykinin antagonists have been administrated to asthmatic subjects, and have shown clinical benefits in bradykinin- and exercise-induced asthma (Fig. 3, 4).[22,23] There are no reported studies of tachykinin antagonists in COPD subjects.[16]

NITRIC OXIDE (NO) AND OTHER OXIDATIVE MOLECULES

Because reactive oxygen and related species including nitric oxide (NO) have a potent proinflammatory action,[24,25] these molecules may be involved in the airway inflammatory process in asthma.[26] In animal models, allergen-[27] and ozone-induced[28] airway inflammation and airway hyperresponsiveness are largely modified by inhibitors of synthesis of reactive oxygen and related species or by scavengers of radical species, supporting this hypothesis. Further, NO hyperproduction due to inducible NO synthase (iNOS) has been shown in asthmatic airways and experimental asthma animal models.[29-33] Steroid treatment reduces the NO generation,[34] suggesting that NO may be partly responsible for the asthmatic airway inflammation.

Other types of reactive oxygen, such as superoxide anion (O_2^-) may also be exaggerated in asthmatic airways via the upregulation of xanthine oxidase (XO) in microvascular endothelial cells and NADPH oxidase in the infiltrated eosinophils.[35] NO rapidly reacts with O_2^- released from inflammatory cells including eosinophils, and results in the formation of the highly proinflammatory molecule peroxynitrite.[36]

NO seems to be involved in the inflammatory mechanism of the late allergic response (LAR) after allergen challenge, which most resembles asthmatic airway inflammation. We have assessed the NO, O_2^- and peroxynitrite production by measuring the NO concentration in the exhaled air, O_2^- generating enzyme activity, and peroxynitrite-induced nitration product immunostaining, respectively. We quantified the airway microvascular permeability by means of Monastral blue dye trapping between the postcapillary endothelium. The functional role of the NO, O_2^- and peroxynitrite on the microvascular permeability was assessed using each molecule's synthase inhibitor or scavenger. Further, we also quantified the eosinophil accumulation into the airways during the LAR and examined the role of NO, O_2^- and peroxynitrite in the eosinophil response. We have reported that peroxynitrite formed by NO and O_2^- is an important molecule for the microvascular hyperpermeability but not the eosinophil accumulation during the late allergic airway responses.[37]

Oxidative stress and defense imbalance may be one of the causes of COPD.[38-41] The large production of NO during inflammatory-immune processes of the respiratory tract is thought to constitute a host defense mechanism, although this comes at a price because a high level of NO can also cause respiratory tract injury and thus contribute to the pathophysiology of inflammatory airway diseases such as COPD and asthma. Recently, excessive nitric oxide (NO) production, presumably via inducible NO synthase (iNOS), has been reported in asthmatic airways,[41] although its presence is controversial in COPD airways.

The adverse effects of NO are thought to be engendered, in part, by its reaction with superoxide anion, which is released from inflammatory cells, yielding the potent oxidant peroxynitrite.[36] Peroxynitrite adds a nitro group to the 3-position adjacent to the hy-



Fig. 3 Dose-response relation to bradykinin in each subject. ○ indicates after placebo and ● indicates after FK 224 (NK 1, 2-antagonist). Reproduced from reference 22.

droxyl group of tyrosine to produce the stable product nitrotyrosine. Alternatively, NO reacts with O_2 to form nitrite. The oxidation of nitrite by neutrophil-derived myeloperoxidase (MPO) or by other related peroxidases[42] results in the formation of nitryl chloride and nitrogen dioxide (NO_2). This mechanism has also been found in inflammatory conditions. Although tyrosine nitration is generally attributed to peroxynitrite, the peroxidase-dependent nitrite oxidation pathway is also involved. Therefore, nitrotyrosine is a collective indicator for the involvement of reactive nitrogen species. We have reported that abundant nitrotyrosine positive staining cells as well as iNOS positive cells were observed in the induced sputum both in COPD and asthmatic patients compared with healthy subjects.[43] The nitrotyrosine positive cells were significantly more obvious in COPD than in asthma, suggesting that the oxidative stress by reac-



Fig. 4 Relation between %predicted FEV_1 and nitrotyrosine (NT)-positive cell counts in induced sputum of asthma and COPD patients. r is correlation coefficient; the line and p value correspond to the fitted regression equation. N.S. , not significant. Reproduced from reference 43.

tive nitrogen species may be exaggerated in the airways of these diseases, especially in COPD. Further, because the nitrotyrosine positive cell counts were significantly correlated with the airway obstructive changes in COPD (Fig. 4),[43] the hyperproduction of reactive nitrogen species may be an important factor in the pathogenesis of COPD. Further, in COPD patients, the steroid-induced improvement in the airway caliber and hyperresponsiveness is significantly correlated with the reduction of the reactive nitrogen species production,[44] indicating that modulation of the reactive nitrogen species may be useful for future COPD therapy.

CONCLUSION

In this review, I have shown some aspects of the differences of the inflammatory processes in asthma and COPD. These differences seem to cause distinct pathological differences between the two diseases.[45]

ACKNOWLEDGEMENTS

The author thank Mr. Brent Bell for reading this manuscript.

M. I. has previously served as a member of scientific advisory boards for GlaxoSmithKline KK, Nippon Boehringer Ingelheim, Novartis Pharma KK, and AstraZeneca KK. He has received lecture fees from GlaxoSmithKline KK, AstraZeneca KK, Nippon Boehringer Ingelheim, and unrestricted grants from GlaxoSmithKline KK and Nippon Boehringer Ingelheim.

REFERENCES

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Available at http://www.ginasthma.org. Accessed March 16, 2009.
2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Bethesda, MD: National Heart, Lung, and Blood Institute. Available at http://www.goldcopd.org. Accessed March 16, 2009.
3. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. *Ann Rev Immunol* 2005;**23**:749-86.
4. Robinson DS. The role of the mast cell in asthma: induction of airway hyperresponsiveness by interaction with smooth muscle? *J Allergy Clin Immunol* 2004;**114**:58-65.
5. Kay AB, Phipps S, Robinson DS. A role for eosinophils in airway remodeling in asthma. *Trends Immunol* 2004;**25**:477-82.
6. Larche M, Robinson DS, Kay AB. The role of T lymphocytes in the pathogenesis of asthma. *J Allergy Clin Immunol* 2003;**111**:450-63.
7. Akbari O, Faul JL, Hoyte EG *et al.* CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma. *N Engl J Med* 2006;**354**:1117-29.
8. Kuipers H, Lambrecht BN. The interplay of dendritic cells, Th2 cells and regulatory T cells in asthma. *Curr Opin Immunol* 2004;**16**:702-8.
9. Peters-Golden M. The alveolar macrophage: the forgotten cell in asthma. *Am J Respir Cell Mol Biol* 2004;**31**:3-7.
10. Wenzel S. Mechanisms of severe asthma. *Clin Exp Allergy* 2003;**33**:622-8.
11. Matsunaga K, Yanagisawa S, Ichikawa T *et al.* Airway cytokine expression measured by means of protein array in exhaled breath condensate: Correlation with physiologic properties in asthmatic patients. *J Allergy Clin Immunol* 2006;**118**:84-90.
12. Tattersfield AE, Knox AJ, Britton JR, Hall IP. Asthma. *Lancet* 2002;**360**:1313-22.
13. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. *Nat Rev Immunol* 2008;**8**:183-92.
14. Traves SL, Smith SJ, Barnes PJ, Donnelly LE. Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. *J Leukoc Biol* 2004;**76**:441-50.
15. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. *Am J Respir Crit Care Med* 1996;**153**:530-4.

16. Barnes PJ. Mediators of chronic obstructive pulmonary disease. *Pharmacol Rev* 2004;**56**:515-48.
17. Lefcoe NM, Toogood JH, Blennerhassett G, Baskerville J, Paterson NA. The addition of aerosol anticholinergic to an oral beta agonist plus theophylline in asthma and bronchitis. A double-blind single dose study. *Chest* 1982;**82**:300-5.
18. Tomaki M, Ichinose M, Miura M *et al.* Elevated substance P content in induced sputum from patients with asthma and patients with chronic bronchitis. *Am J Respir Crit Care Med* 1995;**151**:613-7.
19. Ichinose M, Barnes PJ. The effect of peptidase inhibitors on bradykinin-induced bronchoconstriction in guinea-pigs in vivo. *Br J Pharmacol* 1990;**101**:77-80.
20. Frigas SE, Loegering DA, Gleich GJ. Cytotoxic effects of the guinea pig eosinophil major basic protein on tracheal epithelium. *Lab Invest* 1980;**42**:35-43.
21. Gleich GJ, Loegering DA, Adolphson CR. Eosinophils and bronchial inflammation. *Chest* 1985;**87**:10S-3.
22. Ichinose M, Nakajima N, Takahashi T, Yamauchi H, Inoue H, Takishima T. Protection against bradykinin-induced bronchoconstriction in asthmatic patients by neurokinin receptor antagonist. *Lancet* 1992;**340**:1248-51.
23. Ichinose M, Miura M, Yamauchi H *et al.* A neurokinin 1-receptor antagonist improves exercise-induced airway narrowing in asthmatic patients. *Am J Respir Crit Care Med* 1996;**153**:936-41.
24. Barnes PJ. Reactive oxygen species and airway inflammation. *Free Rad Biol Med* 1990;**9**:235-43.
25. Nathan C. Nitric oxide as a secretary product of mammalian cells. *FASEB J* 1992;**6**:3051-64.
26. Ichinose M, Takahashi T, Sugiura H *et al.* Baseline airway hyperresponsiveness and its reversible component: role of airway inflammation and caliber. *Eur Respir J* 2000;**15**:248-53.
27. Miura M, Ichinose M, Kageyama N *et al.* Endogenous nitric oxide modifies antigen-induced microvascular leakage in sensitized guinea pig airways. *J Allergy Clin Immunol* 1996;**98**:144-51.
28. Takahashi T, Miura M, Katsumata U *et al.* Involvement of superoxide in ozone-induced airway hyperresponsiveness in anesthetized cats. *Am Rev Respir Dis* 1993;**148**:103-6.
29. Hamid Q, Springall DR, Riveros-Moreno V *et al.* Induction of nitric oxide synthase in asthma. *Lancet* 1993;**342**:1510-3.
30. Koarai A, Ichinose M, Sugiura H, Yamagata S, Hattori T, Shirato K. Allergic airway hyperresponsiveness and eosinophil infiltration is reduced by a selective iNOS inhibitor, 1400W, in mice. *Pulm Pharm Ther* 2000;**13**:267-75.
31. Koarai A, Ichinose M, Sugiura H *et al.* iNOS depletion completely diminishes reactive nitrogen species formation after allergic response. *Eur Respir J* 2002;**20**:609-16.
32. Sugiura H, Ichinose M. Oxidative and nitrative stress in bronchial asthma. *Antioxid Redox Signal* 2008;**10**:785-98.
33. Sugiura H, Komaki Y, Koarai A, Ichinose M. Nitrative stress in refractory asthma. *J Allergy Clin Immunol* 2008;**121**:355-60.
34. Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne EA, Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patients. *Lancet* 1994;**343**:133-5.
35. Sedgwick JB. Mechanisms of eosinophil activation. In: Busse WW, Holgate ST (eds). *Asthma and Rhinitis.* Boston: Blackwell Scientific Publications, 1995;285-97.
36. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. *Proc Natl Acad Sci USA* 1990;**87**:1620-4.
37. Sugiura H, Ichinose M, Oyake T *et al.* Role of peroxynitrite in airway microvascular hyperpermeability during late allergic phase in guinea pigs. *Am J Respir Crit Care Med* 1999;**160**:663-71.
38. Pinamonti S, Muzzoli M, Chicca MC *et al.* Xanthine oxidase activity in bronchoalveolar lavage fluid from patients with chronic obstructive pulmonary disease. *Free Radic Biol Med* 1996;**21**:147-55.
39. Rahman I, Morrison D, Donaldson K, MacNee W. Systemic oxidative stress in asthma, COPD, and smokers. *Am J Respir Crit Care Med* 1996;**154**:1055-60.
40. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1997;**156**:341-57.
41. van der Vliet A, Eiserich JP, Shigenaga MK, Cross CE. Reactive nitrogen species and tyrosine nitration in the respiratory tract. *Am J Respir Crit Care Med* 1999;**160**:1-9.
42. Eiserich JP, Hristova M, Cross CE *et al.* Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. *Nature* 1998;**391**:393-7.
43. Ichinose M, Sugiura H, Yamagata S, Koarai A, Shirato K. Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways. *Am J Respir Crit Care Med* 2000;**162**:701-6.
44. Sugiura H, Ichinose M, Yamagata S, Koarai A, Shirato K, Hattori T. Correlation between pulmonary function change and suppression in reactive nitrogen species production following steroid treatment in COPD. *Thorax* 2003;**58**:299-305.
45. Fabbri LM, Romagnoli M, Corbetta L *et al.* Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2003;**167**:418-24.

Respiratory Research

BioMed Central

Research

Open Access

Oxidative stress augments toll-like receptor 8 mediated neutrophilic responses in healthy subjects

Satoru Yanagisawa, Akira Koarai, Hisatoshi Sugiura, Tomohiro Ichikawa, Masae Kanda, Rie Tanaka, Keiichiro Akamatsu, Tsunahiko Hirano, Kazuto Matsunaga, Yoshiaki Minakata and Masakazu Ichinose*

Address: Third Department of Internal Medicine, Wakayama Medical University, School of Medicine, Wakayama, Japan

Email: Satoru Yanagisawa - yngsw@wakayama-med.ac.jp; Akira Koarai - koarai@wakayama-med.ac.jp; Hisatoshi Sugiura - sugiura@wakayama-med.ac.jp; Tomohiro Ichikawa - 1kawa@wakayama-med.ac.jp; Masae Kanda - k97025@yahoo.co.jp; Rie Tanaka - rie-t@wakayama-med.ac.jp; Keiichiro Akamatsu - akamatsu@wakayama-med.ac.jp; Tsunahiko Hirano - tsuna@wakayama-med.ac.jp; Kazuto Matsunaga - kazmatsu@wakayama-med.ac.jp; Yoshiaki Minakata - minakaty@wakayama-med.ac.jp; Masakazu Ichinose* - masakazu@wakayama-med.ac.jp

* Corresponding author

Published: 15 June 2009

Respiratory Research 2009, **10**:50 doi:10.1186/1465-9921-10-50

Received: 10 January 2009
Accepted: 15 June 2009

This article is available from: http://respiratory-research.com/content/10/1/50

© 2009 Yanagisawa et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Excessive oxidative stress has been reported to be generated in inflamed tissues and contribute to the pathogenesis of inflammatory lung diseases, exacerbations of which induced by viral infections are associated with toll-like receptor (TLR) activation. Among these receptors, TLR8 has been reported as a key receptor that recognizes single-strand RNA virus. However, it remains unknown whether TLR8 signaling is potentiated by oxidative stress. The aim of this study is to examine whether oxidative stress modulates TLR8 signaling in vitro.

Methods: Human peripheral blood neutrophils were obtained from healthy non-smokers and stimulated with TLR 7/8 agonist imidazoquinoline resiquimod (R848) in the presence or absence of hydrogen peroxide (H_2O_2). Neutrophilic responses including cytokine release, superoxide production and chemotaxis were examined, and the signal transduction was also analyzed.

Results: Activation of TLR8, but not TLR7, augmented IL-8 release. The R848-augmented IL-8 release was significantly potentiated by pretreatment with H_2O_2 ($p < 0.01$), and N-acetyl-L-cysteine reversed this potentiation. The combination of H_2O_2 and R848 significantly potentiated NF-kB phosphorylation and IkBα degradation. The H_2O_2-potentiated IL-8 release was suppressed by MG-132, a proteosome inhibitor, and by dexamethasone. The expressions of TLR8, myeloid differentiation primary response gene 88 (MyD88), and tumor necrosis factor receptor-associated factor 6 (TRAF6) were not affected by H_2O_2.

Conclusion: TLR8-mediated neutrophilic responses were markedly potentiated by oxidative stress, and the potentiation was mediated by enhanced NF-kB activation. These results suggest that oxidative stress might potentiate the neutrophilic inflammation during viral infection.

Introduction

Reactive oxygen species (ROS) such as hydrogen peroxide (H_2O_2) and superoxide anion are generated in inflamed tissues and are reported to contribute to the pathogenesis of inflammatory lung diseases including chronic obstructive pulmonary diseases (COPD) [1,2], bronchial asthma [3,4], cystic fibrosis [5,6], and idiopathic pulmonary fibrosis [7,8]. Large amounts of ROS derived from inflammatory cells cause pro-inflammatory cytokine production. In fact, H_2O_2 has been reported to augment cytokine production in previous studies [9,10]. Among inflammatory cells, neutrophils are a key player in the inflammatory lung diseases. It is well-known that excessive infiltration of neutrophils is observed in the airways during exacerbations induced by viral infections [11-14].

Toll-like receptors (TLRs) are simple pattern recognition receptor systems and are known to react with conserved molecular patterns of pathogens [15]. The innate immunity cells also act against viral infections through TLRs including TLR3, TLR7 and TLR8. Human neutrophils possess all functional TLRs except TLR3 [16], and their agonists enhance neutrophil functions such as cytokine release, superoxide generation and phagocytosis [16]. TLR7 and TLR8, located in the endosome, act as anti-viral receptors for recognizing single strand RNA (ssRNA) [17-19], which is present at various phases of viral infection from viral entry to replication. After TLR7 and TLR8 are activated by ssRNA, their signals are transduced through myeloid differentiation primary response gene 88 (MyD-88) and tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) leading to enhanced nuclear factor-kappa B (NF-kB) DNA binding activity [20]. Activation of NF-kB leads to increased inflammatory gene products such as interleukin-8 (IL-8) and GM-CSF causing neutrophilic inflammation during viral infection. Resiquimod (R848), a potent synthetic agonist of TLR 7/8 has been reported to simulate the effects of ssRNA viruses on TLR 7/8, to prime human neutrophils [16,21], and then increase the biosynthesis of lipid mediators through NF-kB activation [22] suggesting that TLR7 and TLR8 activation might affect the neutrophilic responses.

Although excessive oxidative stress occurs in the airways of inflammatory lung diseases during exacerbations, it remains unclear whether oxidative stress potentiates the neutrophilic responses against viral infection. Therefore, by using human peripheral neutrophils from healthy never-smoking subjects, the present study was designed to clarify whether oxidative stress can potentiate the TLR8-mediated neutrophilic responses, including cytokine production, chemotaxis and superoxide generation. Furthermore, we also investigated what signal transductions are associated with this potentiation of the neutrophilic responses.

Materials and methods

Reagents

Commercially available reagents were obtained as follows: Mono-Poly Resolving Medium was from Dainippon Pharmaceutical Co. Ltd. (Osaka, Japan); fetal calf serum (FCS) and RPMI medium 1640 (RPMI 1640) were from Invitrogen (Carlsbad, California, USA); R848 (resiquimod: 4-amino-2-etoxymethyl-α,α-dimethyl-1*H*-imidazo [4,5-*c*]quinolin-1-ethanol), bafilomycin and 12-o-tetradecanoylphorbol 13-acetate were from Alexis Biochemicals (San Diego, California, USA); R837 (Imiquimod: 1-isobutyl-1*H*-imidazo [4,5-*c*]quinolin-4-amine) was from Biomol (Plymouth Meeting, Pennsylvania, USA); N-acethyl-L-cysteine, MG-132, dexamethasone and anti-β-actin antibody were from Sigma (St. Louis, Missouri, USA); anti-TLR8 rabbit polyclonal antibody was from Abgent (San Diego, California, USA); Cellfix solution was from Becton Dickinson (San Jose, California, USA); phycoerythrin (PE)- conjugated anti-TLR8 antibody solution was from Imgenex (San Diego, California, USA); dihydrorhodamine-123 (DHR-123) was from Cayman Chemical (Ann Arbor, Michigan, USA); human recombinant IL-8 was from Acris antibodies (Hiddenhausen, Germany); anti-human MyD88 antibody, anti-human TRAF6, and anti-human IkBα were from Santa Cruz (San Diego, California, USA); peroxidase-conjugated secondary antibodies were from Rockland Immunochemicals (Gilbertsville, Pennsylvania, USA)

Isolation of peripheral blood neutrophils

Healthy subjects participated in the present study. They were never-smokers and had had no infection for 4 weeks preceding the study. Human peripheral blood neutrophils were isolated from whole blood by a density gradient technique using Mono-Poly Resolving Medium as previously reported [23]. Briefly, whole blood was collected by vein puncture into tubes containing EDTA anticoagulant. Then, each blood sample was gently mounted onto the same volume of Mono-Poly Resolving Medium without mixing. The samples were centrifuged at 400 × *g* for 20 min at room temperature. The blood was separated into four layers from the top, plasma, lymphocytes/mononuclear cells, neutrophils, and red blood cells. The neutrophil layer was gently collected by a pasteur pipette without aspirating the other layers and put into fresh 20 ml tubes. This procedure allowed us to obtain neutrophils with over 95% purity and viability as determined by trypan blue staining. After washing by phosphate-buffered saline (PBS) solution and counting the cell numbers, neutrophils were suspended in 10% FCS in RPMI 1640 at a concentration of 1×10^6 cells/ml. The neutrophils were isolated before each experiment and used immediately. All replicate experiments in the current study were performed by using neutrophils from different donors. This study was approved by the local ethics committee of

Wakayama Medical University School of Medicine. Informed written consent was obtained from all subjects.

Immunocytochemistory

100 μl of the neutrophil suspension containing 1×10^5 cells were centrifuged by a Cytospin 4 cytocentrifuge (ThermoShandon, ThermoBioAnalysis, Tokyo, Japan) at $25 \times g$ for 5 min. The preparation was fixed in 4% paraformaldehyde fixative solution for 30 min. Endogeneous peroxidase activity was blocked by incubation in 0.3% H_2O_2 in PBS for 15 min at room temperature. After washing, the cells were incubated with anti-TLR8 rabbit polyclonal antibody (1:100 dilution) for 12 hrs at 4°C. Non-specific binding to the antibody was prevented by pre-incubation with 2% bovine serum albumin in PBS containing 0.3% Triton-X for 30 min. The immunoreactions were visualized by the indirect immunoperoxidase method using Envision polymer reagent, which is goat anti-rabbit IgG conjugated with peroxidase labeled dextran (Dako Japan Ltd, Kyoto, Japan), for 1 hour at room temperature. Diaminobenzidine reaction was performed, followed by counterstaining with hematoxirin. The slides were viewed with a microscope (BX-50, Olympus Corporation, Tokyo, Japan) and photographed with a digital camera (c-5050, Olympus Corporation, Tokyo, Japan).

Flow cytometry analysis

The expression of TLR8 in neutrophils was assessed by a FACS calibur flow cytometer (Becton Dickinson, San Jose, CA) according to the manufacturer's instructions. Briefly, 200 μl of the neutrophil suspension containing 2×10^6 neutrophils were first permeabilized by 1 × permeabilizing solution (Becton Dickinson, San Jose, California, USA) for 30 min on ice to stain not only cell surface TLR8 but also endosomal TLR8, and then incubated with 4 μl of PE-conjugated anti-TLR8 antibody solution or its isotype-control for 20 min at 4°C. After washing, the samples were fixed by 500 μl of 1% paraformaldehyde for 10 min. Binding of each antibody was detected using CellQuest analysis software on a FACS Calibur (Becton Dickinson, San Jose, California, USA). Specific binding of each antibody was expressed as relative fluorescence that was calculated by the ratio of the mean fluorescence intensity for TLR8 to the mean fluorescence intensity for the isotype control.

TLR stimulation

Isolated neutrophils were stimulated in 24-well tissue culture plates with various concentrations of R848, a ligand for TLR 7/8, or R837, a ligand for TLR7, for 24 hr at 37°C in a humidified atmosphere of 5% CO_2. Cells were pretreated with various concentrations of H_2O_2 for 30 min prior to the stimulation with R848 [24]. To investigate the effects of the inhibitors or a scavenger on the IL-8 release, cells were further pretreated with each agent prior to the treatment with H_2O_2 as follows: bafilomycin, an inhibitor of endosomal acidification, for 15 min; N-acethyl-L-cysteine was for 10 min; MG-132, a proteosome inhibitor, for 60 min; and dexamethasone for 30 min. Media were harvested at 24 hours after treatment with R848 for subsequent enzyme-linked immunosorbent assays (ELISA) to measure various cytokine levels. Similarly, cells were harvested at the same time for flow-cytometry analysis, or western blotting.

Measurement of cytokines

IL-8 expression was measured by sandwich ELISA (R&D System Europe, Abingdon, UK) according to the manufacturer's instructions. The lower detection limit was 16 pg/ml. The levels of IL-1β, IL-6, IL-10, IL-12 and TNF-α were measured by a Human Inflammation Cytokine Beads array kit (Becton Dickinson, San Jose, California, USA) according to the manufacturer's instructions.

Measurement of superoxide generation

Neutrophils were pre-incubated with or without 50 μM H_2O_2, and then stimulated with various concentrations of R848 for 1 hr at 37°C. Cells were harvested, washed twice and resuspended in 10% FCS in RPMI 1640 at a concentration of 1×10^6 cells/ml. One ml cell suspensions were cultured at 37°C with 3 μM DHR-123 for 5 min and then with 12-o-tetradecanoylphorbol 13-acetate for 30 min at 37°C. The cells were cooled on ice, centrifuged, and resuspended in PBS. Stained cells were assessed by a flow-cytometer (Becton Dickinson, San Jose, California, USA). The amount of superoxide generation was evaluated by the relative fluorescence intensity of DHR-123 compared with that of the control group.

Chemotaxis assay

Neutrophils were pre-incubated with or without 50 μM H_2O_2 and then stimulated with various concentrations of R848 for 1 hr. Cells were harvested, washed twice and resuspended in 10% FCS in RPMI 1640 at a concentration of 2×10^6 cells/ml. Chemotaxis assays were performed on plastic chemotaxis chambers (pore size: 3 μm; Kurabou, Osaka, Japan) according to the manufacturer's instructions. Briefly, 250 μl of RPMI 1640 containing IL-8 (0.3 ng/ml) were placed into the bottom wells and 100 μl of the neutrophil suspension were added into the top wells. The chambers were then incubated in a tissue-culture incubator at 37°C for 1 hr. The numbers of neutrophils that transmigrated to the bottom wells were counted using a flow-cytometer (Becton Dickinson, San Jose, California, USA). Results are shown as the ratio of the migrated cell number of each group to that of the control group.

Elastase assay
Elastase release from the neutrophils was measured by a human PMN elastase ELISA kit (Bender Medsystems, Vienna, Austria) according to the manufacturer's instructions.

Phosflow analysis of phosphorylated NF-kB p65
1×10^6 neutrophils were incubated with or without 50 μM H_2O_2 and stimulated with various concentrations of R848 for 1 hr. The phosphorylated NF-kB p65 levels were measured by the BD phosflow method (Becton Dickinson, San Jose, CA) according to the manufacturer's instructions.

Western blotting
After stimulation, the neutrophils were centrifuged at 400 × g for 10 seconds and incubated on ice for 30 min with cold Triton buffer (1% Triton X-100, 150 mM NaCl, 20 mM Tris-HCl, pH 7.4, 1 mM EDTA, 2 mM diisopropylfluorophosphate, 5 μg/ml pepstatin A and 1 mM phenylmethylsulfonylfluoride). Then, the cell lysates were centrifuged at 12,000 × g for 10 min, collected and stored at -80°C. Cell lysates were mixed with the same volume of 2 × SDS loading buffer and separated with 12.5% gradient polyacrylamide gel (DRC Co. Ltd., Tokyo, Japan). After electrophoresis, the proteins were transferred to a nitrocellulose membrane and incubated with anti-human MyD88 antibody (1:200 dilution), anti-human TRAF6 (1:200 dilution), or anti-human IkBα (1:200 dilution) overnight. To standardize the expression of each protein, the membranes were stripped off and re-probed with anti-β-actin antibody (1:10000 dilution). The membranes were then incubated with the appropriate peroxidase-conjugated secondary antibodies (1:2000 dilution). The bound antibodies were visualized with an ECL-plus detection system (Amersham, Backinghamshire, UK) and photographed by an ECL minicamera (Amersham, Backinghamshire, UK).

Stastical analysis
Data are expressed as mean values ± SEM. Data were analyzed by one way analysis of variance (ANOVA) followed by Bonferroni's test or Sheffe's test to adjust for multiple comparisons. An unpaired two-tailed Student's t-test was used for single comparisons. Probability values of less than 0.05 were considered significant.

Results

Detection of toll-like receptor (TLR) 8 in human polymorphonuclear cells (PMNs) and its reaction to R848
To determine whether human neutrophils express TLR8, we first investigated the expression of TLR8 in neutrophils by immunocytochemistry and flow-cytometry. As shown in Figure 1A, TLR8 was detected by immunocytochemistry. To examine the cellular localization of TLR8, we performed flow-cytometry analysis against TLR8. TLR8 was stained with or without cell membrane permeabilization, indicating that TLR8 exists not only in the cytosol such as the endosome but also on the cell surface (Figure 1B).

We next investigated the effect of TLR7 ligand R837 or TLR 7/8 ligand R848 on the release of IL-8 from neutrophils. R848 increased IL-8 release in a time-dependent manner (Figure 1C). As shown in figure 1D, R848 dose-dependently augmented the release of IL-8 at 24 hr, whereas R837 had no effect. To confirm whether this augmentation of IL-8 release is mediated by TLR signaling, the cells were pretreated with bafilomycin, an inhibitor of endosomal acidification. Pretreatment with bafilomycin significantly inhibited the R848-augmented IL-8 release in a dose-dependent manner (Figure 1E). Dexamethasone also significantly inhibited the R848-augmented IL-8 release (Figure 1F).

Effect of H_2O_2 on R848-augmented cytokine release, superoxide generation, elastase release, and chemotaxis in human PMNs
To examine whether oxidative stress potentiates the R848-augmented IL-8 release, we examined the effects of H_2O_2 on the IL-8 release from neutrophils. Pretreatment with H_2O_2 significantly potentiated the R848-augmented IL-8 release in a dose-dependent manner (Figure 2A). Preincubation with 50 μM H_2O_2 shifted the dose-response curve leftward (Log EC_{50} 2.757 vs. 1.775 μM, $p < 0.01$, Figure 2B). In addition, the maximal response by R848 was also significantly potentiated compared with control (Figure 2B). This potentiation was abolished by an antioxidant, N-acetyl-L-cysteine, compared with the vehicle-pretreatment group (Figure 2C). The effect of R848 on the release of cytokines and the potentiation by H_2O_2 were also examined. As shown in Figure 2D–F, R848 significantly augmented TNF-α, IL-6 and IL-1β release from neutrophils. H_2O_2 potentiated the R848-augmented TNF-α (Figure 2D) and IL-6 release (Figure 2E) as well as IL-8, but H_2O_2 caused no potentiation of the IL-1β release (Figure 2F). Furthermore, we investigated whether H_2O_2 potentiated the R848-induced neutrophilic responses, including superoxide generation, elastase release, and chemotaxis. Neither H_2O_2 nor R848 stimulated superoxide production on their own, but the combination of the two did (Figure 3A), whereas H_2O_2 did not cause any potentiation of the elastase release and chemotactic capacity (Figure 3B and 3C).

Effect of H_2O_2 on the R848-mediated TLR8 signaling
To clarify the mechanisms of the potentiation of the R848-induced neutrophilic responses by H_2O_2, we investigated whether H_2O_2 modulates the NF-kB activation induced by R848, which is a key signaling in TLR activation. Although R848 or H_2O_2 enhanced the phosphorylation of NF-kB p65, the phosphorylation was significantly augmented by the combination of R848 and H_2O_2 (Figure



Figure 1 *(see legend on next page)*

Figure 1 *(see previous page)*
Detection of toll-like receptor (TLR) 8 in human polymorphonuclear cells (PMNs), and the effects of TLR 7/8 ligand R848 on interleukin(IL)-8 release. (A) TLR8 in PMN was detected by immunocytochemistry. Left panel indicates isotype control. Right panel shows TLR8 immunoreactivity in PMN. (Original magnification: × 400, Scale bars = 10 μm). (B) TLR8 expression was analyzed by flow-cytometry. PMNs were stained by anti-human TLR8 (solid lines) or the isotype control (gray histograms) in the permeabilized (left panel) and unpermeabilized condition (right panel). Left panel indicates both intercellular and cell surface expression of TLR8. Right panel shows cell surface expression alone. (C-F) Effect of R848 on the release of IL-8, and effect of bafilomycin or dexamethasone on the R848-induced IL-8 release from PMN. (C) PMNs were treated with 10 μM R848. The media were harvested at various time points and assayed for IL-8 by ELISA. (D) PMNs were treated for 24 hrs with R837, a ligand of TLR7, or various concentrations of R848, a ligand of TLR 7/8. Media were assayed for IL-8 by ELISA. (E, F) PMNs were treated with 10 μM R848 or vehicle in the presence of various concentrations of bafilomycin, an inhibitor of endosomal acidification (E), or dexamethasone (F). Media were assayed for IL-8 by ELISA. All values are mean values ± SEM of three to four separate experiments. *$p < 0.05$, **$p < 0.01$, compared with the values of control; +$p < 0.05$, ++$p < 0.01$, compared with the values of the vehicle-pretreated and 10 μM R848-treated group.

4A). To investigate the mechanisms in the enhancement of NF-kB p65 phosphorylation by H_2O_2, we examined the effect of H_2O_2 on IkBα expression in the presence of R848. As shown in Figure 4B, R848 treatment dose-dependently reduced the IkBα protein levels. Furthermore, 50 μM H_2O_2 significantly reduced the IkBα protein level in the R848-treated cells, suggesting that H_2O_2 could modulate the NF-kB activity through the regulation of IkBα expression. Because NF-kB regulates IL-8 gene expression, we examined the effect of MG-132, a proteosome inhibitor, on the IL-8 release in the presence of R848 and H_2O_2. Pretreatment with MG-132 dose-dependently inhibited IkBα degradation as estimated by western blotting (Additional file 1). MG-132 also significantly reduced the augmented IL-8 release by treatment with R848 and H_2O_2 (Figure 4C). Furthermore, we evaluated whether H_2O_2 affected the amounts of TLR8, MyD88 and TRAF6, which are thought to be key molecules in TLR8 signaling. H_2O_2 did not affect these protein amounts in the presence of R848 (data not shown).

Effect of dexamethasone on the H_2O_2-potentiated IL-8 release

Because steroids have been used for viral infection-induced exacerbations of various pulmonary diseases such as bronchial asthma or COPD, we examined the effect of dexamethasone on the H_2O_2-potentiated IL-8 release in the R848 treated cells. As shown in Figure 5, dexamethasone dose-dependently reduced the H_2O_2-potentiated IL-8 release in the presence of R848. However, the inhibitory effects of dexamethasone were lower in the H_2O_2 and R848 combination treatment group than in the R848 treatment group.

Discussion

In the current study, we have shown that peripheral blood neutrophils from healthy never-smoking subjects expressed TLR8, and that the TLR 7/8 ligand R848, but not the TLR7 ligand, induced IL-8 release from neutrophils. H_2O_2 potentiated the R848-augmented IL-8 release, and this potentiation was reversed by N-acetyl-L-cysteine. In addition, H_2O_2 potentiated the release of TNF-α and IL-6, and the superoxide generation in the R848 treated neutrophils. Although the expressions of TLR8, MyD88 and TRAF6 were not affected by H_2O_2, H_2O_2 enhanced the phosphorylation of NF-kB and potentiated the IkBα degradation in the R848 treated cells. Furthermore, MG-132, a proteosome inhibitor, reversed the H_2O_2-potentiated IL-8 release in the R848 treated neutrophils. These results suggested that oxidative stress potentiated the release of various R848-induced cytokines and superoxide generation in human neutrophils through NF-kB activation.

Previous reports have demonstrated that human peripheral blood neutrophils possessed all known TLRs except TLR3, but the expression levels of TLR7 and its reponses are extremely limited [16]. In the present study, R848, a potent synthetic agonist of TLR 7/8, but not the TLR7 ligand R837, enhanced the neutrophilic responses including the cytokine production (IL-8, TNF-α, IL-6 and IL-1β), the superoxide generation and the chemotaxis of neutrophils. This is consistent with a previous study, which showed that the influenza virus and R848 stimulated the IL-8 release in neutrophils through the activation of TLR 7/8 [21]. It was also shown that TLR7 knockout neutrophils respond poorly to both the TLR 7/8 ligand and the influenza virus in comparison with wild type neutrophils, suggesting that TLR7 plays an essential role in murine neutrophils. These results are inconsistent with our current study. However, several studies have reported that TLR7 stimulation affects the cytokine release not in human neutrophil, but in murine neutrophils [25,26]. These results suggest that the discrepancy of the findings with the previous report might be due to differences in the species.

In the current study, we showed that H_2O_2 potentiated the cytokine release including IL-8, TNF-α, and IL-6, and the



Figure 2 *(see legend on next page)*

Figure 2 *(see previous page)*
Effect of H_2O_2 on the R848-induced cytokine release from human PMNs, and effect of N-acethyl-L-cysteine on the potentiation of cytokine release by H_2O_2. (A) PMNs were incubated with various concentrations of H_2O_2 for 30 min, and then treated with R848 for 24 hrs. Media were assayed for IL-8 by ELISA. (B) Various concentrations of R848 were added to PMNs in the presence or absence of 50 μM H_2O_2. After 24 hrs, IL-8 levels in media were measured by ELISA. Dose-response curve of IL-8 release from PMNs was plotted against the R848 concentration. (C) Ten mM N-acethyl-L-cysteine (NAC) was added 10 min before H_2O_2 or vehicle treatment, then the PMNs were cultured for 24 hrs in the presence or absence of R848. (D-F) Effects of H_2O_2 on TNF-α (D), IL-6 (E) and IL-1β (F) release from the R848-treated PMNs were assessed by Cytokine-Beads Array. All values are mean values ± SEM of three to five separate experiments. **p < 0.01, compared with the values of vehicle-pretreated 1 μM R848-treated group; **p < 0.01, compared with the values of control; ≠≠p < 0.01, compared with the values of vehicle treated group; +p < 0.05, ++p < 0.01, compared with the values of 50 μM H_2O_2-pretreated and vehicle-treated group.

superoxide generation in R848-treated neutrophils. In addition, this potentiation was reversed by N-acethyl-L-cysteine suggesting that oxidative stress is associated with the potentiation of the R848-mediated neutrophilic response. A previous report has shown that H_2O_2 pre-incubation potentiated lipopolysaccharide-induced IL-8 production, and that hydroxy radical scavengers markedly suppressed this potentiation [9,10,27]. These results are consistent with our findings. Although H_2O_2 potentiated the R848-augmented neutrophilic responses, the potentiation seemed to be heterogeneous. Indeed, H_2O_2 potentiated the R848-augmented IL-8, TNF-α, and IL-6 release, but did not potentiate the IL-1β release. This was an interesting finding because the degree of oxidative stress may modulate the profile of inflammatory mediators during viral infection. In the current study, it remained unclear why the potentiation by oxidative stress was heterogeneous. A future study is needed to explore this issue.

Hydrogen peroxide enhanced the R848-induced phosphorylation of NF-kB, and potentiated the degradation of IkBα. In addition, a proteosome inhibitor, MG-132, inhibited the H_2O_2-augmented IL-8 release in the R848-treated neutrophils. Considering that H_2O_2 did not affect the expression levels of TLR8 or other signaling molecules such as MyD88 or TRAF6, these results suggested that the H_2O_2-potentiated NF-kB activation could play a central role in the augmentation of the neutrophilic responses. This was consistent with previous reports, which have shown that oxidative stress cooperatively activated NF-kB with other mediators such as TNF-α [28-30].

In Figure 4A and 4B, the phosphorylation of NF-kB p65 in the vehicle-pretreated and R848-treated group was less than in the H_2O_2-pretreated and vehicle-treated group. In theory, the phosphorylation in the vehicle-pretreated and R848-treated group should be greater than in the H_2O_2-pretreated and vehicle-treated group. There is a possible explanation for this discrepancy. Generally, NF-kB is phosphorylated by NF-kB kinase and IkBα kinases when NF-kB is dissociated from IkBα and translocated into the nucleus in various types of cells [31,32]. There is no report that explored the interaction between NF-kB phosphorylation and IkBα degradation in neutrophils under TLR8 activation. Therefore, the finding observed in the current study may be due to an unknown signaling in the R848-treated neutrophils.

Steroids have been reported to reduce the severity and duration of admission in exacerbations of COPD and asthma. In this study, dexamethasone inhibited the R848-augmented IL-8 release from neutrophils in a dose-dependent manner, and this inhibition was observed in the presence or absence of H_2O_2. These results might indicate that steroids are useful therapeutic agents to attenuate the viral-induced neutrophilic inflammation. However, the pretreatment with H_2O_2 attenuated the effect of dexamethasone, suggesting that oxidative stress induced the steroid resistance. It has been reported that oxidative stress attenuates the effects of steroids in macrophages and epithelial cells through histone deacetylase 2 inactivation [24,33]. This mechanism may also explain the results observed in the present study.

There are several limitations in the current study. First, we used H_2O_2 as a model of oxidative stress. Many previous reports used this in vitro model to mimic the pathophysiological condition of oxidative stress observed in inflammatory lung diseases including COPD and asthma. We used H_2O_2 at 0.1 – 100 μM in the current study and these concentrations are the same range as in previous reports [24,34]. However, we should be careful when extrapolating the findings obtained in this in vitro model to the "real" pathophysiological conditions in inflammatory lung diseases. Second, we used neutrophils isolated from healthy subjects, not from smokers or patients with lung diseases. According to previous reports, the characteristics of neutrophils are altered in patients with COPD compared with healthy subjects [23,35]. The neutrophilic responses to TLR activation may be altered in patients with inflammatory lung disease. Third, we used R848 as a synthetic ligand for TLR 7/8. Many reports have used R848



Figure 3
Effect of H_2O_2 on the R848-induced superoxide generation, elastase release and chemotaxis in human PMNs. (A) PMNs were preincubated for 30 min with or without 50 μM H_2O_2, and treated with vehicle or R848. Cells were then harvested and incubated with dihydro-rhodamine-123 (DHR-123) for 5 min. The amount of superoxide generation was indicated as the relative fluorescence intensity of DHR-123. (B) After incubation with or without 50 μM H_2O_2, PMNs were stimulated with various concentrations of R848 for 24 hrs. The media were assayed for elastase release by ELISA. (C) After one hour treatment with various concentrations of R848 with or without 50 μM H_2O_2, chemotactic capacity toward IL-8 was assessed by a modified boyden chamber method. Vertical axis: Relative ratio of the PMN counts (-fold increase). Relative ratio of the PMN counts was calculated as the ratio of the migrated cell count of each group to that of the control group. All values are mean values ± SEM of three to four separate experiments. *$p < 0.05$, compared with the values of vehicle-treated group; +$p < 0.05$, compared with the values of 50 μM H_2O_2-pretreated and vehicle-treated group; MFI = mean fluorescence intensity.



Figure 4 *(see legend on next page)*